High-Purity Anti-Infective Intermediates Wholesale 2026
Sourcing High-Purity Anti-Infective Related Synthetic Intermediates at Wholesale Scale: What Buyers Need to Know
Global R&D activities focused on antibacterial and antiviral small-molecule chemistry keep driving steady demand for upstream synthetic building blocks and fine chemical intermediates. For procurement teams sourcing high-purity anti-infective related synthetic intermediates in bulk, purchasing decisions rarely hinge on price alone.
Reliable lead times, consistent batch performance, and complete technical documentation for analytical and process development are equally critical considerations. Shandong Tianming Pharmaceutical Group, operating under the brand Tianming Pharmaceutical, has built its corresponding fine chemical product line around these core procurement requirements.
The Core Challenges of Bulk Sourcing for Specialized Heterocyclic Intermediates
Buyers sourcing this category of niche synthetic intermediates often face common supply-side challenges: long lead times for custom specialty chemicals, fluctuating raw material costs, inconsistent batch profiles that disrupt downstream lab and pilot work, and high management costs when sourcing different building blocks from multiple separate vendors.
For structurally complex intermediates, matching process parameters to a customer’s custom synthetic route adds extra complexity. New synthetic route iteration may also outpace the supply readiness of upstream building blocks. These are the typical hurdles that bulk buyers need to evaluate when selecting a reliable chemical partner.
Product Portfolio of Anti-Infective Related Synthetic Intermediates
Tianming Pharmaceutical’s fine chemical lineup covers 18 distinct compounds, including beta-lactamase inhibitor related building blocks, cephalosporin intermediates, antiviral synthetic scaffolds and other small-molecule fine chemicals. The product list includes Avibactam Sodium (CAS 1192491614) and its upstream synthetic precursors:
- O-Benzylhydroxylamine Hydrochloride (CAS 2687-43-6)
- (2S,5R)-Phenoxyamide piperidine-2-carboxylic acid ethyl ester oxalate (CAS 1416134-48-9)
- (2S,5R)-5-[(Benzyloxy)amino]piperidine-2-carboxamide dihydrochloride (CAS 1416134-49-0)
- (2S,5R)-6-Benzyloxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide (CAS 1192651-49-2)
- Avibactam Core Nucleus (CAS 1416134536)
Cephalosporin-related synthetic intermediates include:
- 4-Methylquinazoline-5-carboxaldehyde (CAS 82294-70-0)
- 3,5-Dichloro-4-pyridone-1-acetic acid (DCPA, CAS 56187-37-2)
- 7-ATCA HCl / Cefmenoxime Core Nucleus Hydrochloride (CAS 68350-02-7)
- 7-MTCA: (6R,7R)-7-Amino-3-[(5-methyltetrazol-2-yl)thio]methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (CAS 82549-51-7)
- Benzathine Cefapirin (CAS 97468-37-6)
Antiviral research-oriented fine chemicals in this series:
- Tenofovir Alafenamide Fumarate (CAS 1392275-56-7)
- [[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethyl]methyl]phosphonic acid monophenyl ester (CAS 379270-35-6)
- Tenofovir Alafenamide (CAS 379270-37-8)
- Baricitinib (CAS 1187594-09-7)
- Moxifloxacin (CAS 249243-29-5)
- Baloxavir Marboxil (CAS 1985606-14-1)
Quality Control Standards & Technical Documentation
For bulk buyers, purity data is only valuable when supported by complete supporting records. Tianming Pharmaceutical maintains an ISO9001 certified quality management system; Shandong Sihuan Pharmaceutical Co., Ltd. obtained certification in 2025 and Guangxi Tianming Pharmaceutical Co., Ltd. obtained certification in 2024.
Each shipment is supplied with full COA and structural confirmation documents. The available technical package includes analytical methodology descriptions, impurity profile data and stability study records to support customers’ internal process research and analytical validation. Full batch traceability is implemented across raw material intake, reaction parameters, purification procedures and testing results, with all records properly archived.
Production Layout & Bulk Capacity Support
Bulk procurement requires stable production capacity that can accommodate both small R&D sample orders and larger repeat orders without interruption. Tianming Pharmaceutical operates three coordinated production bases: Shandong Sihuan Pharmaceutical Co., Ltd. (Dezhou), Jining Tianming Pharmaceutical Co., Ltd. (Jining), and Guangxi Tianming Pharmaceutical Co., Ltd. (Hechi).
The combined facility runs more than 160 reactor vessels, with an annual portfolio output at hundreds of tons. The group has over 400 employees, two R&D centers located in Jinan and Nanjing with over 6,000 m² of laboratory space and a technical team of more than 100 researchers. Annual R&D investment exceeds 10% of revenue, above the industry average of around 5%, with an additional 1% of revenue allocated to continuous quality management system optimization.
One-Stop Full-Chain Supply Model for B2B Chemical Procurement
Instead of providing isolated single compounds, Tianming Pharmaceutical delivers integrated supply covering gram-scale lab samples, kilogram pilot batches and large bulk quantities. Services cover pre-sales technical consultation, sample supply, custom synthesis, process optimization, route scale-up, bulk production, logistics arrangement, trade insurance and supporting documentation for international shipments.
In-stock items can be shipped within 7–15 working days after order confirmation, QC review and packaging. Lead times for custom synthesis are determined by synthetic complexity, workshop scheduling and raw material availability. Expedited production can be arranged for time-sensitive R&D projects upon request.
Technical Support & Logistics Assurance
Besides material supply, bulk buyers need fast and reliable technical communication. The company adopts a dual support model: dedicated account manager paired with professional chemical engineer for each project.
- General technical inquiries: reference feedback within 2 hours
- Complex process and analytical questions: formal written report within 24 hours
- On-site technical discussion and regular follow-up are available for framework and bulk cooperation clients.
Logistics options include domestic specialty chemical transport, international air freight, sea freight and courier services. Cold-chain transport is available for temperature-sensitive materials, and nitrogen-filled vacuum packaging is offered for compounds prone to oxidation. All shipments are covered by transport insurance, with compensation and replacement arrangements for quality damage caused during transit.
Company Background & Global Market Coverage
Shandong Tianming Pharmaceutical Group originated from Shandong Sihuan Pharmaceutical Co., Ltd., founded in 2010, and the group structure was formally established in 2020. It is a National High-Tech Enterprise. Shandong Sihuan Pharmaceutical Co., Ltd., Shandong Tianming Pharmaceutical Technology Co., Ltd., and Guangxi Tianming Pharmaceutical Co., Ltd. obtained this qualification in 2024, 2025 and 2023 respectively.
The group serves more than 2,000 domestic partners across major pharmaceutical clusters in East China, North China and South China. Internationally, it supplies customers in over 30 countries and regions including South Asia, Southeast Asia, the Middle East, Central and South America, and Africa, with local business teams in India and Bangladesh.
For procurement teams screening suppliers of high-purity anti-infective related synthetic intermediates in bulk, key due diligence points include the completeness of the chemical portfolio, stable ISO-backed quality control, scalable production capacity and responsive technical after-sales service. Buyers are advised to confirm these details directly with the supplier before placing volume orders.
Disclaimer All products listed are fine chemical intermediates and synthetic building blocks, intended solely for laboratory research, synthetic route exploration and analytical method development. They are NOT for human or animal clinical use, pharmaceutical formulation, or any commercial therapeutic application. No warranty of freedom to operate under any third-party patent is provided. Purchasers shall independently assess patent clearance and compliance for their intended use.
Tianming Pharmaceutical Group
About Author
